FDA Drug recall D-0304-2025
Tolterodine Tartrate Extended-Release Capsules, 2 mg, 30 Capsules (3 x 10) Unit Dose carton, Rx only, Packaged and Distributed by: Major Ph…
- FDA Drug
- Class III
- terminated
- Published 2025-04-09
On 2025-04-09 the FDA classified a Class III recall of Tolterodine Tartrate Extended-Release Capsules, 2 mg, 30 Capsules (3 x 10) Unit Dose carton, Rx only, Packaged and Distributed by: Major Ph… by The Harvard Drug Group, citing failed Dissolution Specifications: Out of specification results obtained during routine stability testing for dissolution.
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-0304-2025 |
| Classification | Class III |
| Status | terminated |
| Initiated | 2025-03-04 |
| Published | 2025-04-09 |
| Last updated | 2026-09-13 11:52 UTC |
| Company | The Harvard Drug Group |
| Distribution | US |
Product
Tolterodine Tartrate Extended-Release Capsules, 2 mg, 30 Capsules (3 x 10) Unit Dose carton, Rx only, Packaged and Distributed by: Major Pharmaceuticals, Indianapolis, IN 46268 USA, NDC 0904-6592-04.
Reason
Failed Dissolution Specifications: Out of specification results obtained during routine stability testing for dissolution.
Identifiers
| code_info | Lot# T05393, Exp. Date: 09/30/2025 |
|---|
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0304-2025%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.